Glaucoma biomarkers under study

Results showed that the PAUL Glaucoma Implant is an effective glaucoma drainage device that provides effective IOP lowering, similar to that achieved with the Baerveldt Glaucoma Implant, but with lower rates of complications

The approach to lowering intraocular pressure reduces medication burden without risking graft rejection

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

The company announced new data on outcomes for both open and narrow angle glaucoma patients.

According to the company, the deal expands its European footprint into Spain and Portugal.

Hundreds of previously-unknown genes could be vital for early detection and treatment.